Meeting
2022 ASCO Annual Meeting
EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
Authors
Mary E.R. O'Brien
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Surrey, United Kingdom
Mary E.R. O'Brien , Luis Paz-Ares , Nitish Jha , Urania Dafni , Kersti Oselin , Libor Havel , Emilio Esteban , Dolores Isla , Alex Martinez-Marti , Martin Faehling , Masahiro Tsuboi , Jong-Seok Lee , Kazuhiko Nakagawa , Jing Yang , Steven M. Keller , Murielle Mauer , Sandrine Marreaud , Rolf A. Stahel , Benjamin Besse , Solange Peters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02504372
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8512)
DOI
10.1200/JCO.2022.40.16_suppl.8512
Abstract #
8512
Poster Bd #
139
Abstract Disclosures